RT Journal Article SR Electronic T1 Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP 292 OP 296 DO 10.3899/jrheum.160459 VO 44 IS 3 A1 Rada V. Moerman A1 Suzanne Arends A1 Petra M. Meiners A1 Arjan Vissink A1 Frederik K.L. Spijkervet A1 Frans G.M. Kroese A1 Elisabeth Brouwer A1 Hendrika Bootsma YR 2017 UL http://www.jrheum.org/content/44/3/292.abstract AB Objective. We used the 28-joint Disease Activity Score (DAS28) and the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI) articular domain to assess the effect of rituximab (RTX) and abatacept (ABA) on articular involvement in primary Sjögren syndrome (pSS).Methods. Patients with pSS treated with RTX (n = 18) or ABA (n = 13) and having a DAS28 erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP) level ≥ 3.2 at baseline were selected. Generalized estimating equations were used to analyze the DAS28 and ESSDAI articular domain over time.Results. In the RTX group, DAS28-ESR/CRP decreased significantly up to 48 weeks. In the ABA group, DAS28-ESR/CRP decreased significantly up to 24 weeks. DAS28 correlated significantly with ESSDAI articular domain.Conclusion. DAS28 is useful to evaluate the effect of biologicals on articular involvement in patients with pSS.